Abstracts Archive - Page 982 of 2425 - ACR Meeting Abstracts

Abstract Number: 415 • 2019 ACR/ARP Annual Meeting
Validation of a Satisfaction Measure for Use in Total Joint Replacement Clinical Trials
Susan Goodman¹, Bella Mehta ², Cynthia Kahlenberg ³, Jackie Finik ⁴, Mark Figgie ⁵, Michael Parks ², Douglas Padgett ³, Vinicius Antao ³, Adolf Yates ⁶, Bryan Springer ⁷, Stephen Lyman ³ and Jasvinder Singh ⁸, ¹Hospital For Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery/Weill Cornell Medicine, New York, ³Hospital for Special Surgery, New York, ⁴Hospital for Special Surgery, New York, NY, New York, NY, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ⁶University of Pittsburgh School of Medicine Shadyside, Pittsburgh, ⁷OrthoCarolina Hip and Knee Center, Charlotte, ⁸University of Alabama Medical Center, Birmingham
Background/Purpose: Patient satisfaction after total hip (THR) and total knee replacement (TKR) is a core outcome selected by the Outcomes Measurement in Rheumatology (OMERACT), yet…
Abstract Number: 416 • 2019 ACR/ARP Annual Meeting
Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review
Josep Verges¹, Marianna Vitaloni ¹, Rosa Sciortino ², Maritza Quintero ², Marco Bibas ¹, Jordi Monfort ³, Francisco de Abajo ⁴, Marco Matucci-Cerinic ⁵, Patrick du Souich ⁶, Ingrid Möller ⁷, Guy Eakin ⁸ and Angie Botto-van Bemden ⁸, ¹Osteoarthritis International Foundation, Barcelona, Spain, ²De los Andes University, Merida, Venezuela, ³Hospital del Mar, Barcelona, Spain, ⁴Universidad de Alcalá, Madrid, Spain, ⁵University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ⁶University of Montreal, Montreal, Canada, ⁷Poal Institute, Barcelona, Spain, ⁸Arthritis Foundation, Atlanta
Background/Purpose: Knee OA (KOA) associates with remarkable functional restrictions due to pain that seriously affect social and emotional well-being, reducing the quality of life (QoL).…
Abstract Number: 417 • 2019 ACR/ARP Annual Meeting
Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis
Mart A.F.J. van de Laar¹, Janet Pope ², Yvonne Lee ³, Bruno Fautrel ⁴, Kei Ikeda ⁵, Amanda Quebe ⁶, Xiang Zhang ⁶, Carol Gaich ⁶, Francesco De Leonardis ⁶, Jeffrey Lisse ⁶, Jennifer Workman ⁶, Roy Fleischmann ⁷, Mark Genovese ⁸ and Peter Taylor ⁹, ¹Arthritis Center Twente, Enschede, Netherlands, ²Western University, London, ON, Canada, ³Northwestern University Feinberg School of Medicine, Chicago, ⁴Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁵Chiba University Hospital, Chiba, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁸Stanford University, Stanford, CA, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, has shown clinical efficacy and patient-reported pain relief in patients (pts) with RA and…
Abstract Number: 418 • 2019 ACR/ARP Annual Meeting
Work Productivity Is Associated with Disease Activity and Functional Ability in Chinese Patients with Axial Spondyloarthritis Using a Smart-Phone Management System: A Prospective Cohort Study
Xiaofei Liu ¹, Yanyan Wang ², Wenji Chen ¹, Shiyan Mo ³, Xiaojian Ji ⁴ and Feng Huang², ¹Department of Rheumatology,Hainan Hospital of PLA General Hospital,, sanya, Hainan, China (People's Republic), ²Department of Rheumatology, Chinese PLA General Hospital, beijing, China (People's Republic), ³Department of Rheumatology,Hainan Hospital of PLA General Hospital,, sanya, ⁴Department of Rheumatology, Chinese PLA GeneralHospital,, Beijing, Beijing, China (People's Republic)
Background/Purpose: Axial spondyloarthritis (axSpA) usually affects young people and may lead to work disability(WD). We used the "Smart-phone SpondyloArthritis Management System”, an interactive mobile health…
Abstract Number: 419 • 2019 ACR/ARP Annual Meeting
Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study
Panagiotis Athanassiou ¹, Ioannis Kallitsakis ², Gkikas Katsifis ³, Anastasios Kotrotsios ⁴, Georgios Vosvotekas ⁵, Panagiotis Georgiou ⁶, Andreas Bounas ⁷, Yiannis Haratsis ⁸, Evangelia Petrikkou ⁸ and Dimitrios Vassilopoulos⁹, ¹General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ²Private Practice, Chania, Greece, ³Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, ⁴Private Practice, Karditsa, Greece, ⁵Euromedica General Clinic of Thessaloniki, Rheumatology Clinic, Thessaloniki, Greece, ⁶General Hospital of Patras “Agios Andreas”, Patras, Greece, ⁷Olympion therapeutirion, Patras, Greece, ⁸Merck Sharp & Dohme Pharmaceutical, Industrial and Commercial S.A, Medical Affairs, Athens, Greece, ⁹2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece
Background/Purpose: There are limited real life data regarding the effect of golimumab on work productivity and activity impairment in rheumatic diseases. The aim of our…
Abstract Number: 420 • 2019 ACR/ARP Annual Meeting
Assessment of Fatigue in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Qualitative Study to Explore What Patients Feel Should Be Measured in Clinical Trials
Sally Mannix¹, Andrea Beyer ², Vibeke Strand ³, Leslie Hanrahan ⁴, Cristina Abel ⁵, Bruno Flamion ² and Asha Hareendran ⁶, ¹Evidera, Bethesda, ²Idorsia Pharmaceuticals, Allschwil, Switzerland, ³Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁴Lupus Foundation of America, Washington DC, ⁵Evidera, Bethesda, MD, ⁶Evidera, London, United Kingdom
Background/Purpose: Fatigue is one of the most common symptoms reported by patients with systemic lupus erythematosus (SLE) and is responsible for considerable loss of time at work…
Abstract Number: 421 • 2019 ACR/ARP Annual Meeting
An Examination of Patient-Reported Outcomes Data from a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Vibeke Strand¹, Philip Mease ², Ervant Maksabedian ³, Bradley Stolshek ³, Lyrica Liu ³, David Collier ³, Gregory Kricorian ³ and Joseph Merola ⁴, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ³Amgen Inc., Thousand Oaks, CA, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Health-related quality of life is impacted in patients (pts) with psoriatic arthritis (PsA). Patient-reported outcomes (PROs) are an important means of measuring treatment improvements…
Abstract Number: 422 • 2019 ACR/ARP Annual Meeting
The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis
Vibeke Strand¹, Pankaj Patel ², Naijun Chen ² and Elizabeth M Lesser ³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago
Background/Purpose: Physical function and health-related quality of life (HRQoL) are negatively impacted in patients (pts) with PsA, and treatment with conventional and biological (b) DMARDs…
Abstract Number: 423 • 2019 ACR/ARP Annual Meeting
Patient Reported Outcomes over 2 Years in Psoriatic Arthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Routine Care – Was PRO Remission Achieved? Results from the EuroSpA Collaboration
Lykke Midtbøll Ørnbjerg¹, Lennart Jacobsson ², Anne Gitte Loft ³, Florenzo Iannone ⁴, Michael J. Nissen ⁵, Eirik Kristianslund ⁶, Herman Mann ⁷, Maria José Santos ⁸, Manuel Pombo-Suarez ⁹, Kari K. Eklund ¹⁰, Ziga Rotar ¹¹, Bjorn Gudbjornsson ¹², Mehmet Akif Öztürk ¹³, Catalin Codreanu ¹⁴, Marleen van de Sande ¹⁵, Johan Wallman ¹⁶, Ennio Giulio Favalli ¹⁷, Burkhard Moeller ¹⁸, Joe Sexton ¹⁹, Karel Pavelka ⁷, Elsa Vieira-Sousa ²⁰, Carlos Sánchez-Piedra ²¹, Nina Trokovic ²², Matija Tomsic ²³, Thorvardur J Love ²⁴, Ayşe Cefle ²⁵, Ruxandra IONESCU ²⁶, Irene van der Horst-Bruinsma ¹⁵, Gareth Jones ²⁷, Cecilie Heegaard Brahe ²⁸, Merete Lund Hetland ¹ and Mikkel Østergaard ²⁹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ³Department of Rheumatology, Aarhus University Hospital., Aarhus, Denmark, ⁴Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁵University Hospital Geneva, Geneva, Switzerland, ⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁷Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁸Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁹Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹⁰ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹¹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹²Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, ¹⁴Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁶Department of Clinical Sciences Lund, Rheumatology Lund University, Lund, Sweden, ¹⁷University of Milan, Department of Rheumatology, ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ¹⁸University Hospital Bern, Bern, Switzerland, ¹⁹Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ²⁰Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²¹Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²²Helsinki University Central Hospital, Helsinki, Finland, ²³Department of Rheumatology, University Medical Centre, Ljubjana, Slovenia, ²⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²⁵Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ²⁶SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁷University of Aberdeen, Aberdeen, United Kingdom, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Patient Reported Outcomes (PROs) provide important information on assessment of pain, disease activity, fatigue and physical function in patients with psoriatic arthritis (PsA). Knowledge…
Abstract Number: 424 • 2019 ACR/ARP Annual Meeting
A Novel Patient-Reported Outcome Measure in IgG4-Related Disease: The Symptom Severity Index
Tyler Harkness¹, Karen Donelan ¹, Xiaoqing Fu ¹, Rachel Wallwork ¹, Cory Perugino ¹, John Stone ² and Zachary Wallace ¹, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) causes symptoms, the severity of which vary by organ involvement. The Responder Index (RI) captures physicians’ judgement of disease activity, but…
Abstract Number: 425 • 2019 ACR/ARP Annual Meeting
Differences in Correlation Between Objective Disease Measurements and Patient’s/physician’s Global Assessment in the Large Non-interventional Study SUSTAIN
Jörg Wendler ¹, Peter Wagener ², Schwarze Ilka ³, Evgenia Movshovich⁴, Nils Damann ⁴ and Frank Behrens ⁵, ¹Rheumatologische Schwerpunktpraxis, Erlangen, Germany, ²Fachpraxis für Rheumatologie und Osteologie, Bruchhausen-Vilsen, Germany, ³Praxis für Innere Medizin und Rheumatologie, Leipzig, Germany, ⁴Janssen-Cilag, Neuss, Germany, ⁵Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany
Background/Purpose: The wish of a treating physician is to make sure, that the patient gets an effective and safe therapy and is satisfied with the…
Abstract Number: 426 • 2019 ACR/ARP Annual Meeting
Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo
Dafna Gladman¹, Laura Coates ², Joseph Wu ³, Lara Fallon ⁴, Ming-Ann Hsu ⁵, Andrew Bushmakin ³, Elizabeth Bacci ⁶, Joseph Cappelleri ³ and Philip Helliwell ⁷, ¹University of Toronto, Toronto, ON, Canada, ²University of Oxford, Oxford, United Kingdom, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Montreal, QC, Canada, ⁵Pfizer Inc, Collegeville, PA, ⁶Evidera, Seattle, WA, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: With many disease domains affected in PsA, clinical and patient-reported outcome (PRO) measures are important to assess disease improvement following treatment. Rapid, meaningful improvements…
Abstract Number: 427 • 2019 ACR/ARP Annual Meeting
Correlation Between Patient Reported Outcomes Measurement Information System (PROMIS) and RAPID3 in Rheumatoid Arthritis Patients Starting a New Biologic DMARD
Tyler Williams¹, M. Elaine Husni ², Yuxuan Jin ³, Greg Strnad ¹, Sage O'Bryant ¹ and Chad Deal ⁴, ¹Cleveland Clinic, Cleveland, OH, ²Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ³Quantitative Health Science, Cleveland Clinic, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: RAPID3 is a disease activity measure which relies on patient-reported outcomes (PROs) to assess physical function, pain, and global health but does not require…
Abstract Number: 428 • 2019 ACR/ARP Annual Meeting
Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus
Srita Chakka¹, Rebecca Krain ¹, Sarah Ahmed ², Josef Concha ¹, Rui Feng ³ and Victoria Werth ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA
Background/Purpose: To date, there are no approved treatments for cutaneous lupus erythematosus (CLE), a disease known to significantly burden a patient’s quality of life (QoL).…
Abstract Number: 429 • 2019 ACR/ARP Annual Meeting
Concordance Between Physician and Patient Assessment of Disease Activity in Rheumatoid Arthritis Using Disease Activity Score: Phase II Results
Nelly Ziade¹, Samar Alemadi ², Mohammad Abu Jbara ³, Sahar Saad ⁴, Lina El-Kibbi ⁵, Manal Al-Mashaleh ⁶, Bassel El-Zorkany ⁷, Georges Merheb ⁸, Elie Alam ⁹, Alla Aiko ¹⁰, Jamil Messaykeh ¹¹, Nelly Salloum ¹², Amani Daher ¹, Hussein Halabi ¹³, Kamel Mroue' ¹⁴, Basel Masri ¹⁵, Humeira Badsha ¹⁶, Ghita Harifi ¹⁶ and Thurrayya Arayssi ¹⁷, ¹Saint-Joseph University, Beirut, Lebanon, ²Hamad medical corporation, Doha, Qatar, ³Jordan, Amman, Jordan, ⁴King Hamad University Hospital, Bahrain, Bahrain, ⁵Specialized Medical Center, Riyadh, Saudi Arabia, ⁶King Hussein Medical Center, Amman, Jordan, ⁷Cairo University, Cairo, Egypt, ⁸Holy Spirit University of Kaslik, Kaslik, Lebanon, ⁹Levant Hospital, Beirut, Lebanon, ¹⁰Beirut, Beirut, Lebanon, ¹¹Monla Hospital, Tripoli, Lebanon, ¹²RN, Beirut, Lebanon, ¹³King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia, ¹⁴Bahman Hospital, Beirut, Lebanon, ¹⁵Jordan Hospital, Amman, Jordan, ¹⁶Dr Humeira Badsha Medical Center, Dubai, United Arab Emirates, ¹⁷Weill Cornell Medicine-Qatar, Doha, Qatar
Background/Purpose: Involving patients with rheumatoid arthritis (RA) in the assessment of their disease may increase adherence to treatment, improve disease outcomes and reduce consultation time.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].